Header and Body 4

Advantages

  • Promising in vivo pre-clinical data indicating therapeutic value of targeting glutaminase in KEAP1/NRF2 dysregulated NSCLC tumors
  • KEAP1/NRF2 dysregulation can be used as a theranostic to identify patients for glutaminase therapy